More on B-cell-depleting induction therapy and acute cellular rejection. by Hoogen, M.W.F. van den & Hilbrands, L.B.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;12 nejm.org september 17, 20091214
contribute to the discourse concerning the nu-
ances of the clinical use of fomepizole. Rehman 
points out that the osmolal gap dissipates as eth-
ylene glycol or methanol is metabolized. The rea-
son is that only the parent compound contributes 
to this gap. Electroneutrality requires the acidic 
metabolites of ethylene glycol and methanol (pri-
marily glycolate and formate), which are ionized 
to negatively charged carboxyl groups at physio-
logic pHs, to have a counter cation. In plasma, on 
a probabilistic basis, this would be a sodium ion. 
The equation for calculating the osmolal gap in-
cludes, for serum osmolarity, a term that is two 
times the sodium concentration, accounting for 
both the sodium ion itself and, by virtue of the 
coefficient, the metabolite anion (Table 3 of the 
article). Thus, these metabolites, unlike the par-
ent compounds, will not contribute to the calcu-
lated osmolarity and hence decrease the osmolal 
gap. This event is important because the disap-
pearance of the osmolal gap is evidence of me-
tabolism of the parent compound, after which 
there is no benefit to inhibiting alcohol dehydro-
genase. Rehman also correctly observes that the 
contribution of ethanol must be factored into the 
calculation of the predicted osmolarity (also ex-
plained in Table 3 of the article).
González-Santiago and Garza-Ocañas specu-
late that the pharmacokinetic interaction be-
tween fomepizole and ethanol might exacerbate 
the potential adverse effects of the latter. When 
fomepizole is used, ethanol continues to be me-
tabolized, but with a reduction in the clearance 
rate of approximately 40%.1 There have been a 
number of instances in which fomepizole was 
administered to patients with blood alcohol con-
centrations in the intoxication range with no 
reported adverse effect, including one instance 
in which the fomepizole nullified an adverse ef-
fect of ethanol on a patient’s level of conscious-
ness.2 I agree with González-Santiago and Garza-
Ocañas that fomepizole should be used with 
caution if a patient is allergic to pyrazoles; how-
ever, no allergic reactions in patients with intol-
erance to this class of medications have been re-
ported in the literature.
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More on B-Cell–Depleting Induction Therapy and Acute 
Cellular Rejection
To the Editor: We read with interest the letter 
by Clatworthy et al. (June 18 issue)1 describing their 
use of rituximab as compared with daclizumab 
for induction therapy in patients undergoing re-
nal transplantation. We were surprised, however, 
not only by their finding that  significantly more 
rejection episodes occurred in patients treated with 
rituximab but also by their interpretation of that 
finding, in which they state that rituximab may 
have had a rejection-provoking effect.
We have been using rituximab as part of a de-
sensitization protocol,2 and in 150 ABO-incompat-
ible renal transplantations in Sweden we have not 
seen any increase in rejection episodes. On the 
contrary, because the number of rejections in pa-
tients receiving rituximab has been exceptionally 
small, we recently published a report of a ran-
domized, double-blind, placebo-controlled, mul-
ticenter study in which the effect of administer-
ing a single dose of rituximab was compared 
with the use of placebo as induction therapy in 
renal transplantation (ClinicalTrials.gov number, 
NCT00255593).3 Working with a total of 140 en-
rollees, we found a tendency toward fewer (11.6% 
vs. 17.6%) and milder rejections during the first 
6 months in the rituximab group and observed 
no increase in infectious complications or leuko-
penia in that group.
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Our findings highlight the value of conducting 
randomized, blinded, placebo-controlled studies 
as opposed to drawing conclusions based on in-
cidental observations.
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To the Editor: Clatworthy et al. report the pre-
mature termination of a clinical trial after the 
occurrence of acute rejection in five of six patients 
who received rituximab as B-cell–depleting induc-
tion therapy after renal transplantation. We are 
currently carrying out a study in which 280 pa-
tients undergoing renal transplantation will be 
randomly assigned to receive rituximab (375 mg 
per square meter of body-surface area) or placebo 
during surgery; patients in both study groups 
will also receive tacrolimus, mycophenolate mo-
fetil, and corticosteroids (ClinicalTrials.gov num-
ber, NCT00565331). Prompted by the disquieting 
findings of Clatworthy et al., we analyzed the data 
we had on the first 65 patients in the trial who 
had reached a follow-up of 6 months. In the pa-
tients treated with rituximab, the relative risk of 
acute rejection confirmed by biopsy during the first 
6 months after transplantation was 0.53 (95% con-
fidence interval, 0.21 to 1.32). Tydén et al. recently 
reported an incidence of acute rejection with ri-
tuximab of 12% versus 18% with placebo (not sig-
nificant, P = 0.32) during the first 6 months after 
transplantation.1 Like Clatworthy et al. and Tydén 
et al., we found no difference between the two 
groups in the frequency of infections or cancer 
(according to preliminary data). On the basis of 
these reassuring results, we are proceeding with 
the enrollment of patients.
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The Authors Reply: In their letters, both Tydén 
et al. and van den Hoogen and Hilbrands report 
on recent studies in which the use of rituximab 
in patients undergoing transplantation did not re-
sult in an increase in acute rejection but rather 
resulted in nonsignificant trends toward a lower 
rejection rate. Although these results initially seem 
incompatible with our observation that rituximab 
may increase the rate of acute rejection, careful 
consideration of the different protocols used in 
the three studies indicates that this is probably 
not the case. 
In our study, we proposed that the increase in 
rejection that we observed might be due to a 
mechanism through which B-cell depletion re-
sulted in systemic release of cytokines, thereby 
enhancing T-cell activation and increasing the risk 
of acute rejection. This interpretation is consistent 
with the increased cytokine levels measured in 
our patients and with the transient increase in 
inflammation seen on the initiation of rituximab 
in the treatment of some autoimmune diseases. 
As we stated, if rituximab had been administered 
to patients before transplantation, as it is when 
used in desensitization or ABO-incompatibility 
protocols, such a cytokine storm would have re-
solved before transplantation and no increase in 
the risk of rejection would therefore be expected. 
We think it is also likely that ongoing corticos-
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teroid therapy, used in the protocols of the studies 
conducted by Tydén et al. and van den Hoogen 
and Hilbrands, could suppress the effects of cy-
tokine release, which would explain why the in-
crease in acute rejection seen in our corticoster-
oid-free protocol was not observed in the other 
studies. Comparison of the three studies thus 
highlights the possibility that rituximab therapy 
can induce rejection, perhaps through systemic 
release of cytokines, if it is administered at the 
time of transplantation and without concurrent 
administration of corticosteroids.
Tydén et al. state that conclusions should not 
be drawn from our results. We disagree strongly 
with this statement. We did not claim that our 
study was conclusive but rather urged caution. 
Nonetheless, our results constitute a potentially 
clinically important, statistically significant ob-
servation made in a randomized, controlled study 
with the “hard” end point of rejection confirmed 
by biopsy. It is important to publish such results 
— indeed, their publication has made possible a 
comparison with the results reported by Tydén et 
al. and van den Hoogen and Hilbrands, providing 
insight into the circumstances in which, and the 
mechanism by which, rituximab might increase 
the risk of acute rejection, and suggesting strat-
egies that might be used to avoid this outcome. 
The process has therefore been of potential ben-
efit to patient care.
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A Classic Twin Study of External Ear Malformations,  
Including Microtia
To the Editor: The pathogenesis of microtia, a 
rare congenital malformation of the external ear, 
remains elusive. Phenotypes range from minor 
deformities, such as preauricular tags, to anotia, 
the complete absence of the external ear (Fig. 1). 
Prevalence ranges from 0.66 per 10,000 in En-
gland to 17.4 per 10,000 in Quito, Ecuador.1 The 
relative contributions of environmental and ge-
netic factors to microtia were assessed in a clas-
sic twin study.
In this study, we identified 13 monozygotic and 
22 dizygotic twin pairs at three microtia recon-
struction centers, one in the United States, one in 
Ecuador, and one in Colombia. In other words, 
each twin pair was ascertained because at least 
one sibling had severe nonsyndromic microtia re-
quiring surgical repair. There was no ear malfor-
mation in 40% of subjects, malformation of the 
right ear in 34%, malformation of the left ear in 
13%, and bilateral anomalies in 12%. Ear-malfor-
mation laterality was indistinguishable among 
monozygotic and dizygotic twins. None of the 
twins reported first-degree relatives with ear mal-
formations, but 20% had at least one, more dis-
tant relative with an ear malformation.
The concordance rate for all auricular malfor-
mations was higher in monozygotic twins than 
in dizygotic twins (61.5% and 4.5%, respectively; 
P = 0.003) (Table 1). Concordance rates for micro-
tia (excluding skin tags and minor pinna malfor-
mation) among monozygotic and dizygotic twins 
were also significantly different — 38.5% and 
4.5%, respectively (Table 1).
A literature review identified 37 twin pairs with 
microtia in whom other auricular malformations 
were rarely reported.2-5 When the results of this 
study are combined with those of our study of 35 
twin pairs, the 72 sets of twins show significant 
differences in the concordance rate for monozy-
gotic twins (10 in 38, or 26.3%), and the concor-
dance rate for dizygotic twins (1 in 34, or 2.9%) 
(odds ratio, 11.5; 95% confidence interval, 1.4 to 
93.7; P = 0.023).
In summary, twin studies indicate that there 
is a strong genetic contribution to malformations 
of the external ear. Shared genotype in monozy-
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